NO20065137L - Vannloselig prolegemiddel - Google Patents

Vannloselig prolegemiddel

Info

Publication number
NO20065137L
NO20065137L NO20065137A NO20065137A NO20065137L NO 20065137 L NO20065137 L NO 20065137L NO 20065137 A NO20065137 A NO 20065137A NO 20065137 A NO20065137 A NO 20065137A NO 20065137 L NO20065137 L NO 20065137L
Authority
NO
Norway
Prior art keywords
water soluble
soluble prodrug
prodrug
represented
water
Prior art date
Application number
NO20065137A
Other languages
English (en)
Inventor
Jun Ohwada
Sawako Ozawa
Isao Umeda
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20065137L publication Critical patent/NO20065137L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Vannløselig prolegemiddel representert med generell formel (1), hvor R' er hydrogen eller C1-C6-alkyl, W er en toverdig gruppe som inneholder tertiært amino eller sulfonyl, og Y er en rest av en forbindelse som har en alkoholisk hydroksygruppe og er representert med Y-OH. Det beskrives også et farmasøytisk akseptabelt salt av prolegemidlet, eller et hydrat av dette, eller et solvat av begge.
NO20065137A 2004-04-09 2006-11-08 Vannloselig prolegemiddel NO20065137L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004115713 2004-04-09
PCT/JP2005/006957 WO2005097803A1 (ja) 2004-04-09 2005-04-08 新規水溶性プロドラッグ

Publications (1)

Publication Number Publication Date
NO20065137L true NO20065137L (no) 2006-12-21

Family

ID=35124997

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065137A NO20065137L (no) 2004-04-09 2006-11-08 Vannloselig prolegemiddel

Country Status (18)

Country Link
US (1) US7910593B2 (no)
EP (1) EP1757609B1 (no)
JP (1) JP4823894B2 (no)
KR (1) KR20070011457A (no)
CN (1) CN1964979B (no)
AU (1) AU2005230994A1 (no)
BR (1) BRPI0509732A (no)
CA (1) CA2563502A1 (no)
HK (1) HK1100083A1 (no)
IL (1) IL178465A0 (no)
MX (1) MXPA06011679A (no)
MY (1) MY145850A (no)
NO (1) NO20065137L (no)
NZ (1) NZ550665A (no)
RU (1) RU2413731C2 (no)
TW (1) TWI351284B (no)
UA (1) UA88008C2 (no)
WO (1) WO2005097803A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050044570A (ko) * 2001-11-23 2005-05-12 추가이 세이야쿠 가부시키가이샤 종양 표적 효소의 동정 방법
EP1599484A2 (en) * 2003-02-21 2005-11-30 Chugai Seiyaku Kabushiki Kaisha Process for the preparation of hexacyclic camptothecin derivatives
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
BRPI0509732A (pt) 2004-04-09 2007-09-25 Chugai Pharmaceutical Co Ltd pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
KR20080066039A (ko) * 2005-10-19 2008-07-15 추가이 세이야쿠 가부시키가이샤 신규 수용성 프로드러그를 함유하는 췌장암, 난소암 또는 간암의 예방 또는 치료제
JP5466006B2 (ja) * 2006-09-03 2014-04-09 テックフィールズ バイオケム カンパニー リミテッド 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ
CN102665757A (zh) * 2009-12-09 2012-09-12 免疫医疗公司 通过双特异性抗体预靶向的用于细胞毒性药物的递送系统
EP2914600A2 (en) * 2012-10-30 2015-09-09 Nerviano Medical Sciences S.r.l. Functionalized 9-bromo-camptothecin derivatives
MA44629A (fr) 2016-04-04 2021-03-24 Chemocentryx Inc Antagonistes de c5ar solubles
WO2019059344A1 (ja) 2017-09-22 2019-03-28 大日本住友製薬株式会社 化学活性化型水溶性プロドラッグ
RS63715B1 (sr) 2019-03-29 2022-11-30 Medimmune Ltd Jedinjenja i njihovi konjugati

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
DE3682874D1 (de) 1985-10-21 1992-01-23 Daiichi Seiyaku Co Pyranoindolizinderivate und verfahren zu ihrer herstellung.
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US4939255A (en) 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
JPH0271836A (ja) * 1988-09-05 1990-03-12 Agency Of Ind Science & Technol 繊維状極小分子集合体の製法
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
HU213136B (en) 1990-08-14 1997-02-28 Kyorin Seiyaku Kk Process for producing fluoroethyl camptothecin derivatives and pharmaceutical compositions containing them
JP3008226B2 (ja) 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
ZA922180B (en) 1991-03-29 1993-09-27 Lilly Co Eli Piperidine derivatives
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
GB9402934D0 (en) 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
JP2967184B2 (ja) * 1996-03-07 1999-10-25 工業技術院長 オリゴペプチド鎖のｃ端を両端にもつ双頭型脂質の製造方法
US6172230B1 (en) 1996-04-26 2001-01-09 Daiichi Pharmaceutical Co., Ltd. Process for the preparation of tetrahydro-indolizines
CA2264227A1 (en) 1996-09-27 1998-04-02 Raymond A. Firestone Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
UA57757C2 (uk) 1996-12-20 2003-07-15 Сос'Єте Де Консей Де Решерш Е Даплікасьон С'Єнтіфік (С.К.Р.А.С.) Аналоги камптотецину, спосіб їх отримання (варіанти) і фармацевтична композиція
PT1017675E (pt) 1997-02-14 2006-09-29 Bionumerik Pharmaceuticals Inc Derivados da camtotecina altamente lipofilos
US6294344B1 (en) 1997-03-19 2001-09-25 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
AU7582298A (en) 1997-05-19 1998-12-11 Johns Hopkins University School Of Medicine, The Tissue specific prodrug
DE69837170T2 (de) 1997-06-13 2007-11-22 Amylin Pharmaceuticals, Inc., San Diego Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
GB9715821D0 (en) 1997-07-25 1997-10-01 Pharmacia & Upjohn Spa Amidino-camptothecin derivatives
JP2001512830A (ja) 1997-08-08 2001-08-28 ニューバイオティックス インコーポレイテッド 生物療法耐性および化学療法耐性を克服するための方法および組成物
JP4102466B2 (ja) 1997-11-14 2008-06-18 株式会社アミノアップ化学 抗癌剤の副作用軽減剤
US6130039A (en) 1997-12-12 2000-10-10 Incyte Pharmaceuticals, Inc. Polynucleotide encoding human lysyl hydroxylase-like protein
ES2172303T3 (es) 1998-01-23 2002-09-16 Newbiotics Inc Agentes terapeuticos obtenidos por catalisis enzimatica.
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
WO2003045942A2 (en) 1998-09-04 2003-06-05 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
AU3281600A (en) 1999-02-27 2000-09-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases
WO2000063418A1 (en) * 1999-04-15 2000-10-26 The Regents Of The University Of California Protein transport assays
PL365999A1 (en) 1999-05-14 2005-01-24 Imclone Systems Incorporated Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US7413536B1 (en) * 1999-09-14 2008-08-19 Xenoport, Inc. Substrates and screening methods for transport proteins
US6268375B1 (en) 1999-12-29 2001-07-31 Research Triangle Institute 10, 11-difluoromethylenedioxycamptothecin compounds with topoisomerase I inhibition
CZ298259B6 (cs) 2000-02-28 2007-08-08 Aventis Pharma S. A. Farmaceutická kombinace k lécení rakoviny obsahující CPT-11 a capecitabin
AU2001268653A1 (en) * 2000-06-28 2002-01-08 Supergen, Inc. Combination hiv therapy including camptothecin
EP1358612A2 (en) * 2000-07-28 2003-11-05 LION Bioscience AG Regional intestinal permeability model
WO2002058694A2 (en) 2000-11-07 2002-08-01 Dana-Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers using beta lapachone
US6350756B1 (en) * 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
EP1409711A4 (en) * 2001-03-02 2005-08-10 Iams Company COMPOSITIONS AND METHODS FOR INCREASING AMINO ACID ABSORPTION OF MAMMALS
EP1406493A4 (en) * 2001-06-11 2006-06-14 Xenoport Inc ADMINISTRATION OF MEDIUM BY THE PEPT-2 TRANSPORTER
KR20050044570A (ko) 2001-11-23 2005-05-12 추가이 세이야쿠 가부시키가이샤 종양 표적 효소의 동정 방법
BR0214615A (pt) 2001-11-30 2004-09-14 Chugai Pharmaceutical Co Ltd Composto hexacìclico
WO2004012662A2 (en) * 2002-08-01 2004-02-12 Aesgen, Inc. Improved treatment of cancer with glutamine
PA8578001A1 (es) 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
EP1599484A2 (en) 2003-02-21 2005-11-30 Chugai Seiyaku Kabushiki Kaisha Process for the preparation of hexacyclic camptothecin derivatives
JP2005255643A (ja) 2004-03-15 2005-09-22 Masato Kusunoki 抗腫瘍効果増強方法および抗腫瘍効果増強剤
BRPI0509732A (pt) 2004-04-09 2007-09-25 Chugai Pharmaceutical Co Ltd pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco
DE602005015231D1 (de) 2004-09-02 2009-08-13 Vertex Pharma Als ionenkanalmodulatoren geeignete chinazoline
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
KR20080066039A (ko) * 2005-10-19 2008-07-15 추가이 세이야쿠 가부시키가이샤 신규 수용성 프로드러그를 함유하는 췌장암, 난소암 또는 간암의 예방 또는 치료제

Also Published As

Publication number Publication date
BRPI0509732A (pt) 2007-09-25
EP1757609A1 (en) 2007-02-28
JPWO2005097803A1 (ja) 2008-02-28
US20080015157A1 (en) 2008-01-17
US7910593B2 (en) 2011-03-22
JP4823894B2 (ja) 2011-11-24
RU2006139644A (ru) 2008-05-20
AU2005230994A1 (en) 2005-10-20
MXPA06011679A (es) 2007-01-23
MY145850A (en) 2012-04-30
CN1964979A (zh) 2007-05-16
CA2563502A1 (en) 2005-10-20
HK1100083A1 (en) 2007-09-07
CN1964979B (zh) 2011-07-27
RU2413731C2 (ru) 2011-03-10
TWI351284B (en) 2011-11-01
NZ550665A (en) 2010-05-28
IL178465A0 (en) 2007-02-11
KR20070011457A (ko) 2007-01-24
EP1757609A4 (en) 2010-09-01
EP1757609B1 (en) 2013-10-16
WO2005097803A1 (ja) 2005-10-20
TW200600088A (en) 2006-01-01
UA88008C2 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
NO20065137L (no) Vannloselig prolegemiddel
WO2006113552A3 (en) Cyanoarylamines
EA017861B9 (ru) Способ получения 4-оксохинолинового соединения
NZ592533A (en) METHOD FOR THE PREPARATION OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO]-5-METHOXY-BENZAMIDE, A FACTOR Xa INHIBITOR
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
UA80834C2 (en) Method of synthesising ivabradine and the salts thereof for addition to a pharmaceutically acceptable acid
EP1854789A4 (en) CHINAZOLINE DERIVATIVE WITH TYROSINE KINASE HEMMENDER EFFECT
RS51200B (sr) (imidazol-1-il-metil)-piridazin kao blokator nmda receptora
WO2005105749A3 (en) Process for making montelukast and intermediates therefor
TW200700397A (en) Novel hsp90 inhibitor
NO20084127L (no) Benzylfenylglukopyranosidderivat
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
MXPA06012595A (es) Analogos de amino-tetrazoles y metodos de uso.
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
MX2009006907A (es) Activador de glucocinasa.
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
SG170049A1 (en) Novel 11 beta - hydroxyandrosta-4-ene-3-ones
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
JO2413B1 (en) Benzoxazine derivatives and their use
TW200704633A (en) Process for the preparation of sulfonamide derivatives
PL378201A1 (pl) Sposób farmaceutyczny oraz związki wytwarzane tym sposobem
WO2006021653A3 (fr) Derives d'azasucre, inhibiteurs d'heparanases, leur procede de preparation, les compositions en contenant, leur utilisation
WO2007014839A3 (en) Cathepsin k inhibitors
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application